Presentations

Full Year Report January – December 2018 – Presentation

February 14, 2019

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio.

Redeye – CEO interview

February 4, 2019

BioArctic announced on February 4 that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease. Interview with CEO Gunilla Osswald here.

Aktiespararna Life Science in Stockholm

January 21, 2019

Gunilla Osswald, CEO, presented BioArctic at Aktiespararna’s Life Science evening event in Stockholm, Sweden, on January 21.

Interview with Gunilla Osswald, CEO

December 14, 2018

Gunilla Osswald, CEO, was interviewed by Klas Palin, life science analyst at Redeye, in Stockholm on December 14, 2018.

DNB’s Annual Nordic Healthcare Conference in Oslo

December 12, 2018

Gunilla Osswald, CEO, presented BioArctic at DNB’s 9th Nordic Healthcare Conference in Oslo, Norway, on December 12.

Nordea Tech & Medtech/Life Science Seminar in Stockholm

November 27, 2018

Gunilla Osswald, CEO, presented BioArctic at the Nordea Tech & Medtech/Life Science Seminar in Stockholm, Sweden, on November 27.

Stora Aktiedagen in Stockholm

November 26, 2018

Gunilla Osswald, CEO, presented BioArctic at the “Stora Aktiedagen” in Stockholm, Sweden, on November 26.

Jefferies 2018 London Healthcare Conference

November 15, 2018

Gunilla Osswald, CEO, presented BioArctic at Jefferies 2018 London Healthcare Conference.

Biotech and Money in London

November 13, 2018

Gunilla Osswald, CEO, presented BioArctic at Biotech and Money, Investival Showcase, on November 13 in London.

Interim Report January – September 2018 – Presentation

November 8, 2018

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects.

Redeye CNS Biotech Seminar

October 4, 2018

Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye CNS Biotech Seminar in Stockholm, Sweden.

Interim Report January – June 2018 – Presentation

August 23, 2018

Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease

Redeye Growth Day

June 4, 2018

Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye Growth Day in Stockholm, Sweden.

Annual General Meeting 2018

May 15, 2018

Presentation at BioArctic AB's Annual General Meeting 2018.

Interim Report January – March 2018 – Presentation

April 26, 2018

Continued progress of the project portfolio.

Carnegie Healthcare Seminar 2018

March 14, 2018

Gunilla Osswald, PhD, CEO, presented BioArctic at the Carnegie Healthcare Seminar 2018 on March 14 in Stockholm, Sweden.

11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry, Zurich, Switzerland

February 26, 2018

Gunilla Osswald, CEO of BioArctic AB, presented the company at the 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech ...